Cardiol Therapeutics (CRDL) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Strategic focus and mission

• Developing innovative therapies targeting chronic inflammation in heart diseases, aiming to modify disease progression and improve quality of life for patients with inflammatory cardiac conditions.

• Advancing late-stage clinical programs, including a pivotal Phase 3 trial for recurrent pericarditis and a Phase 2 trial for acute myocarditis.

• Targeting inflammasome activation to downregulate pro-inflammatory mediators without immunosuppression, offering a therapeutic advantage over current treatments.

• Significant market opportunity, with IL-1 blocker therapies generating $500 million annually and forecasts reaching $1 billion.

• Awarded FDA Orphan Designation for the lead program, covering the entire pericarditis landscape in the US.

Clinical development and trial results

• Phase 2 Maverick study in recurrent pericarditis showed rapid, sustained pain reduction and normalization of C-reactive protein, with 71% of patients remaining pain-free during the extension phase.

• The Phase 3 Maverick program aims to enroll 110 patients at 20 centers, focusing on patients with high relapse risk after IL-1 blocker therapy.

• The Archer Phase 2 program in acute myocarditis enrolled 100 patients across five countries, with top-line data expected in early Q2.

• Subcutaneous formulation of the lead drug is being advanced for heart failure, showing promising preclinical results in reducing cardiac remodeling and fibrosis.

• Near-term catalysts include first patient enrollment in Phase 3 pericarditis trial, 50% enrollment completion this year, and top-line data from myocarditis and heart failure programs.

Market landscape and unmet needs

• Recurrent pericarditis affects about 38,000 patients in the US, many of whom are nonresponsive or intolerant to first-line therapies and face limited options beyond immunosuppressants.

• IL-1 blockers, the current third-line therapy, are expensive ($280,000 per patient/year) and associated with dependency and increased infection risk.

• The new oral, non-immunosuppressive therapy aims to fill the gap for patients who fail first-line treatments.

• Acute myocarditis, often affecting young adults, currently lacks any FDA- or EMA-approved therapies, with significant mortality and morbidity.

• Heart failure remains a major global health challenge, with high mortality rates and limited effective treatments for diastolic dysfunction.